CH638401A5 - Process for the preparation of haemoglobin preparations having an increased oxygen delivery - Google Patents
Process for the preparation of haemoglobin preparations having an increased oxygen delivery Download PDFInfo
- Publication number
- CH638401A5 CH638401A5 CH504577A CH504577A CH638401A5 CH 638401 A5 CH638401 A5 CH 638401A5 CH 504577 A CH504577 A CH 504577A CH 504577 A CH504577 A CH 504577A CH 638401 A5 CH638401 A5 CH 638401A5
- Authority
- CH
- Switzerland
- Prior art keywords
- hemoglobin
- solution
- treated
- preparation
- value
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 33
- 229910052760 oxygen Inorganic materials 0.000 title claims description 22
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims description 21
- 239000001301 oxygen Substances 0.000 title claims description 21
- 238000000034 method Methods 0.000 title claims description 14
- 230000008569 process Effects 0.000 title claims description 8
- 102000001554 Hemoglobins Human genes 0.000 claims description 49
- 108010054147 Hemoglobins Proteins 0.000 claims description 49
- 239000000243 solution Substances 0.000 claims description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 31
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 29
- 210000003743 erythrocyte Anatomy 0.000 claims description 22
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 17
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 17
- 229960001327 pyridoxal phosphate Drugs 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- 229960001031 glucose Drugs 0.000 claims description 7
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 229960000380 propiolactone Drugs 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- 239000003792 electrolyte Substances 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 238000005185 salting out Methods 0.000 claims description 2
- 239000012670 alkaline solution Substances 0.000 claims 2
- 239000007795 chemical reaction product Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- CEEQUQSGVRRXQI-UHFFFAOYSA-N Pyridoxal 5-phosphate monohydrate Chemical compound O.CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O CEEQUQSGVRRXQI-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- XOHUEYCVLUUEJJ-UWTATZPHSA-N 2,3-bisphospho-D-glyceric acid Chemical compound OP(=O)(O)O[C@@H](C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UWTATZPHSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- UMHJEEQLYBKSAN-UHFFFAOYSA-N Adipaldehyde Chemical compound O=CCCCCC=O UMHJEEQLYBKSAN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000001295 genetical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- OADYBSJSJUFUBR-UHFFFAOYSA-N octanedial Chemical compound O=CCCCCCCC=O OADYBSJSJUFUBR-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19762617822 DE2617822C3 (de) | 1976-04-23 | 1976-04-23 | Verfahren zur Herstellung eines für die intravenöse Injektion geeigneten Hämoglobinpräparates mit erhöhter Sauerstoffabgabe gegenüber Erythrozyten |
| DE19772714252 DE2714252C2 (de) | 1977-03-31 | 1977-03-31 | Verfahren zur Herstellung eines für die intravenöse Injektion geeigneten Hämoglobinpräparates mit erhöhter Sauerstoffabgabe gegenüber Erythrozyten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH638401A5 true CH638401A5 (en) | 1983-09-30 |
Family
ID=25770369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH504577A CH638401A5 (en) | 1976-04-23 | 1977-04-22 | Process for the preparation of haemoglobin preparations having an increased oxygen delivery |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS52154515A (enrdf_load_stackoverflow) |
| CH (1) | CH638401A5 (enrdf_load_stackoverflow) |
| GB (1) | GB1576752A (enrdf_load_stackoverflow) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3144705C2 (de) * | 1981-11-11 | 1983-12-08 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat |
| JPS5899420A (ja) * | 1981-12-04 | 1983-06-13 | Ajinomoto Co Inc | 人工血液用酸素運搬剤 |
| US4826811A (en) * | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| JPS63192402U (enrdf_load_stackoverflow) * | 1987-05-27 | 1988-12-12 | ||
| JPH03501545A (ja) * | 1987-12-03 | 1991-04-04 | クローライド サイレント パワー リミテッド | 改良アルカル金属電池 |
| JPH0225503U (enrdf_load_stackoverflow) * | 1988-08-05 | 1990-02-20 |
-
1977
- 1977-04-20 JP JP4459377A patent/JPS52154515A/ja active Granted
- 1977-04-22 GB GB1681677A patent/GB1576752A/en not_active Expired
- 1977-04-22 CH CH504577A patent/CH638401A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS52154515A (en) | 1977-12-22 |
| JPS6133805B2 (enrdf_load_stackoverflow) | 1986-08-04 |
| GB1576752A (en) | 1980-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3790322C2 (de) | Nichtzellulares Präparat als Ersatz für rote Blutkörperchen | |
| US4136093A (en) | Hemoglobin preparation with increased oxygen release | |
| EP0912197B1 (de) | Hämoglobin-hydroxyethylstärke-konjugate als sauerstoff-transport-mittel | |
| DE2417619C2 (de) | Intramolekular vernetztes Hämoglobin, Verfahren zu dessen Herstellung und seine Verwendung | |
| DE3144705C2 (de) | Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat | |
| DE2646854C2 (enrdf_load_stackoverflow) | ||
| DE2449885C3 (de) | Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat | |
| DE3877811T2 (de) | Pasteurisierbares, lyophilisierbares blutsurrogat auf haemoglobinbasis. | |
| EP0265865B1 (de) | Blutersatzmittel | |
| DE2607706A1 (de) | Wasserloesliches, polymerisiertes haemoglobin | |
| EP1294386A1 (de) | Künstliche sauerstoffträger aus vernetztem modifizierten human- oder schweinehämoglobin, verfahren zu ihrer herstellung aus gereinigtem material, sowie deren verwendung | |
| DE3110128A1 (de) | Verfahren und vorrichtung zur entgiftung und regeneration von blut, blutbestandteilen und bei der blutreinigung anfallenden loesungen sowie kit fuer die durchfuehrung des verfahrens | |
| DE2624815B2 (de) | Herstellung einer injizierbaren, stromafreien und von Plasmaproteinen freien Hämoglobinlösung | |
| WO2002000229A1 (de) | Verfahren zur herstellung künstlicher sauerstoffträger aus kovalent vernetzten hämoglobinen mit verbesserten funktionellen eigenschaften durch vernetzung in anwesenheit chemisch nicht reagierender effektoren der sauerstoffaffinität der hämoglobine | |
| EP3041495B1 (de) | Zubereitungen zur verbesserten gewebe-oxygenierung durch peritoneale beatmung | |
| DE69332106T2 (de) | Lösung für die Peritonealdialyse | |
| NZ211101A (en) | Glucose polymer containing compositions for use in peritoneal dialysis | |
| DE69130736T2 (de) | Methode für die präparation von pyridoxyliertem hämoglobin | |
| DE69722422T2 (de) | Verfahren und vorrichtung zur herstellung eines zellfreien ersatzes roter blutzellen | |
| CH638401A5 (en) | Process for the preparation of haemoglobin preparations having an increased oxygen delivery | |
| EP1326893A2 (de) | Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung | |
| DE2617822C3 (de) | Verfahren zur Herstellung eines für die intravenöse Injektion geeigneten Hämoglobinpräparates mit erhöhter Sauerstoffabgabe gegenüber Erythrozyten | |
| DE3101001A1 (de) | Verfahren zur konzentration und reinigung des antihaemophilie-faktors oder faktor viii | |
| DE69031335T2 (de) | Dextrinderivate und deren Verwendung bei der Behandlung von Vergiftungen | |
| DE10055703A1 (de) | Verhinderung der Zellzerstörung und Beseitigung sklrotischer Amyloide verursacht durch organspezifische Antikörperaggregate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PFA | Name/firm changed |
Owner name: BIOTEST AKTIENGESELLSCHAFT |
|
| PL | Patent ceased |